Pergolide in Parkinson's disease: Time for a change? [2]

Lancet

Volumn 363, Issue 9424, 2004, Pages 1907-1908

  Grosset, Katherine A ^a   Grosset, Donald G ^a  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ANTIPARKINSON AGENT;

CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; NOTE;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HEART VALVE DISEASES; HUMANS; PARKINSON DISEASE; PERGOLIDE;

EID: 2942620377     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16369-1     Document Type: Letter

References (3)

1. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 363:2004;1179-1183
2. Grosset KA, Needleman F, Macphee G, Grosset DG. Switching from ergot to non-ergot dopamine agonists in Parkinson's disease: a clinical series and 5 drug dose conversion table. Mov Dis (in press).
3. Stewart DA, Morgan E, Burn D, et al. Dopamine agonist switching in Parkinson's disease. Hosp Med. 65:2004;215-219